Structure-Activity Study on a Novel Series of Macrocyclic Inhibitors of the Hepatitis C Virus NS3 Protease Leading to the Discovery of BILN 2061

Journal of Medicinal Chemistry

Volumn 47, Issue 7, 2004, Pages 1605-1608

  Llinàs Brunet, Montse ^a   Bailey, Murray D ^a   Bolger, Gordon ^a   Brochu, Christian ^a   Faucher, Anne Marie ^a   Ferland, Jean Marie ^a   Garneau, Michel ^a   Ghiro, Elise ^a   Gorys, Vida ^a   Grand Maître, Chantal ^a   Halmos, Ted ^a   Lapeyre Paquette, Nicole ^a   Liard, Francine ^a   Poirier, Martin ^a   Rhéaume, Manon ^a   Tsantrizos, Youla S ^a   Lamarre, Daniel ^a  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMIC ACID; CILUPREVIR; ENZYME INHIBITOR; HYDROXYPROLINE; NS3 PROTEASE; NS3 PROTEASE INHIBITOR; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS ENZYME;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HEPATITIS C; HEPATITIS C VIRUS; NONHUMAN; RAT; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; CARBAMATES; HEPACIVIRUS; HETEROCYCLIC COMPOUNDS; INJECTIONS, INTRAVENOUS; PROLINE; PROTEASE INHIBITORS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS;

EID: 12144290054     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0342414     Document Type: Article

References (29)

1. Choo, Q.-L.; Kuo, G.; Weiner, A. J.; Overby, L. R.; Bradley, D. W.; Houghton, M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome Science 1989, 244, 359.
2. Hagedorn, C. H.; Rice, C. M. The hepatitis C virus. Curr. Top. Microbiol. Immunol. 2000, 242.
3. World Health Organization: Hepatitis C. Seroprevalence of hepatitis C virus (HCV) in a population sample. Wkly Epidemiol. Rec. 1996, 71, 346-349.
4. Cornberg, M.; Wedemeyer, H.; Manns, M. P. Treatment of chronic hepatitis C with PEGylated interferon and rivavarin. Curr. Gastroenterol. Rep. 2002, 4, 23-30.
5. Reed, K. E.; Rice, C. M. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr. Top. Microbiol. Immunol. 2000, 242, 55-84.
6. Beaulieu, P. L.; Llinàs-Brunet, M. Therapies for Hepatitis C Infection: Targeting the Non-Structural Proteins of HCV. Curr. Med. Chem.: Anti-Infect. Agents 2002, 1, 163-176.
7. Lesk, A. M.; Fordham, W. D. Conservation and variability in the structure of serine proteinases of the chymotrypsin family. J. Mol. Biol. 1996, 258, 501-537.
8. Steinkuhler, C.; Koch, U.; Narjes, F.; Matassa, V. G. Hepatitis C Virus Serine Protease Inhibitors: Current Progress and Future Challenges. Curr. Med. Chem. 2001, 8, 919-932.
9. Kolykhalov, A. A.; Mihalik, K.; Feinstone, S. M.; Rice, C. M. Hepatitis C Virus-Encoded Enzymatic Activities and Conserved RNA Elements in the 3′ Nontranslated Region Are Essential for Virus Replication in Vivo. J. Virol. 2000, 74, 2046.
10. Llinàs-Brunet, M.; Bailey, M.; Fazal, G.; Goulet, S.; Halmos, T.; Laplante, S.; Maurice, R.; Poirier, M.; Poupart, M.-A.; Thibeault, D.; Wernic, D.; Lamarre, D. Peptide-based inhibitors of the hepatitis C virus serine protease. Bioorg. Med. Chem. Lett. 1998, 8, 1713-1718.
11. Steinkühler, C.; Biasiol, G.; Brunette, M.; Urbani, A.; Koch, U.; Cortese, R.; Pessi, A.; De Francesco, R. Product inhibition of the hepatitis C virus NS3 protease. Biochemistry 1998, 37, 8899-8905.
12. Llinàs-Brunet, M.; Bailey, M.; Fazal, G.; Ghiro, E.; Gorys, V.; Goulet, S.; Halmos, T.; Maurice, R.; Poirier, M.; Poupart, M.-A.; Rancourt, J.; Thibeault, D.; Wernic, D.; Lamarre, D. Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors. Bioorg. Med. Chem. Lett. 2000, 10, 2267-2270.
13. Pause, A.; Kukolj, G.; Bailey, M.; Brault, M.; Dô, F.; Halmos, T.; Lagacé, L.; Maurice, R.; Marquis, M.; McKercher, G.; Pellerin, C.; Pilote, L.; Thibeault, D.; Lamarre, D. An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis C virus RNA. J. Biol. Chem. 2003, 278, 20374-20380.
14. Goudreau, N.; Cameron, D. R.; Bonneau, P.; Gorys, V.; Plouffe, C.; Poirier, M.; Lamarre, D.; Llinàs-Brunet, M. NMR Structural Characterization of Peptide Inhibitors Bound to the HCV NS3 Protease: Design of a New P2 Substituent. J. Med. Chem. 2004, 47, 123-132.
15. Rancourt, J.; Cameron, D.; Gorys, V.; Lamarre, D.; Poirier, M.; Thibeault, D.; Llinàs-Brunet, M. Peptide-Based Inhibitors of the Hepatitis C Virus NS3 Protease: Structure-Activity Relationship at the C-Terminal Position. J. Med. Chem., in press.
16. Tsantrizos, Y. S.; Bolger, G.; Bonneau, P.; Cameron, D. R.; Goudreau, N. ; Kukolj, G.; LaPlante, S. R.; Llinàs-Brunet, M.; Nar, H.; Lamarre, D. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. Angew. Chem., Int. Ed. 2003, 42, 1356-1360.
17. Lamarre, D.; Anderson, P.; Bailey, M.; Beaulieu, P.; Bolger, G.; Bonneau, P.; Bös, M.; Cameron, D.; Cartier, M.; Cordingley, M.; Faucher, A.-M.; Goudreau, N.; Kawai, S.; Kukolj, G.; Lagacé, L.; LaPlante, S.; Narjes, H.; Poupart, M.-A.; Rancourt, J.; St-George, R.; Sentjens, R. E.; Simoneau, B.; Steinmann, G.; Thibeault, D.; Tsantrizos, Y.; Weldon, A. M.; Yong, C.-L.; Llinàs-Brunet, M. Discovery of BILN 2061-An NS3 preotease inhibitors with first antiviral proof-of-concept in humans infected with hepatitis C virus. Nature 2003, 426, 186-189.
18. Tsantrizos, Y. S.; et al. Manuscript in preparation.
19. Llinàs-Brunet, M.; Bailey, M.; Déziel, R.; Fazal, G.; Gorys, V.; Goulet, S.; Halmos, T.; Maurice, R.; Poirier, M.; Poupart, M.-A.; Rancourt, J.; Thibeault, D.; Wernic, D.; Lamarre, D. I. Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease. Bioorg. Med. Chem. Lett. 1998, 8, 2719-2724.
20. Poupart, M.-A.; Cameron, D. R.; Chabot, C.; Ghiro, E.; Goudreau, N.; Goulet, S.; Poirier, M.; Tsantrizos, Y. Solid-phase synthesis of peptidomimetic inhibitors for the hepatitis C virus NS3 protease. J. Org. Chem. 2001, 66, 4743-4751.
21. LaPlante, S. R.; Cameron, D. C.; Aubry, N.; Lefebvre, S.; Kukolj, G.; Maurice, R.; Thibeault, D.; Lamarre, D.; Llinàs-Brunet, M. Solution structure of substrate-based ligands when bound to hepatitis C virus NS3 protease domain. J. Biol. Chem. 1999, 274, 18618-18624.
22. LaPlante, S. R.; Aubry, N.; Bonneau, P. R.; Kukolj, G.; Lamarre, D.; Lefebvre, S.; Li, H.; Llinàs-Brunet, M.; Plouffe, C.; Cameron, D. R. NMR line-broadening and transferred NOESY as a medicinal chemistry tool for studying inhibitors of the hepatitis C virus NS3 protease domain. Bioorg. Med. Chem. Lett. 2000, 10, 2271-2274.
23. 50) were determined using the assays described in ref 13. The values reported are an average of at least four determinations.
24. Greene, T. W., Wuts, P. G. M., Eds. Protective Groups in Organic Synthesis, 3rd ed.; John Wiley & Sons: New York, 1999; p 518.
25. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 1-3, 3-25.
26. Rats were administered compounds as either an oral gavage or intravenous bolus dose in a vehicle consisting of PEG400/water (70:30). Protocols for the experiments are described in the supporting information of ref 16.
27. Denissen, J. F.; Grabowski, B. A.; Johnson, M. K.; Buko, A. M.; Kempf, D. J.; Thomas, S. B.; Surber, B. W. Metabolism and disposition of the HIV-1 protease inhibitors Ritonavir (ABT-538) in rats, dogs and humans. Drug Metab. Dispos. 1995, 23, 185-189.
28. Tsantrizos, Y. S.; Cameron, D.; Faucher, A.-M.; Ghiro, E.; Goudreau, N.; Halmos, T.; Llinàs-Brunet, M.; Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the Hepatitis C virus. U.S. Patent 6,608, 027 B1, 2003.
29. Yoakim, C.; Guse, I.; O'Meara, J. A.; Thavonekham, B. Removable Phosphine Reagents for the Mitsunobu Reaction. Synlett 2003, 473-476.